Skip to content

Inspection Record

Plasma Industries Belgium SCRL — FDA 483 Findings

US FDAInspected 2018-03-16Published 2026-10-26 7 findingsRegulatory reporting and change controlDocumentation and recordsDeviation, CAPA, and investigationEquipment and facility

View the regulator's official source The source document is always the basis for judgement.

Findings

1Regulatory reporting and change control

The change to the use ofa new at) for the(D) (4), ¢the (BD) (4) was implemented on February 27, 2018 however the associated change control (Change Control 92345) remained open as of March 15, 2018.

2Documentation and records

There is no written justification for the clarifying imits of(b) (4) as stated in Document 2262 / 14.0 entitle 261 — Appendix |: Production File which is a portion ofthe batch record.

3Deviation, CAPA, and investigation

The following deviations (Events) related to (b) (4) were not initiated in a timely manner or are otherwise inadequate: A.

4Equipment and facility

The preventative maintenance program for the hich is used to prepare — (b) (4) for the rocess and the used for CIP was not adequately conducted in year 2016 and 2017.

5Deviation, CAPA, and investigation

As per Document(b) (4) 16 entitled “Particle Contamination” a deviation (Event) is not required to be initiated for the detection ofparticles until particle identification is(b) (4) which is allowed to

6Equipment and facility

Discoloration resembling®) @was observed on (b) (4) located in the (®) (4)of the Operations Building Room () ()during a walkthrough ofthe area on 3-12-18.

7Deviation, CAPA, and investigation

The current procedure for CIP of the fails to require the initiation of a deviation when an atypical event is detected during the ) ifically, CAPA 81235 was initiated as part ofEvent Record 79659 to update SO clean.

A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Plasma Industries Belgium SCRL company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.